Global Anal and Colorectal Cancer Market Hits $13.6 billion in 2025 with 4.3% CAGR

Global anal and colorectal cancer market was valued at $13.6 billion in 2025 and is growing at a CAGR of 4.3% during the forecast period (2026-2035). Accelerated regulatory pathways for innovative oncology therapies targeting high-risk or recurrent cancer populations are fostering investment and expediting clinical development, thereby positively impacting market growth. For instance, in May 2025, the FDA granted fast-track designation to NG-350A for treating mismatch repair proficient locally advanced rectal cancer (LARC). This oncolytic immunotherapy, developed by Akamis Bio, is a T-SIGn therapy delivered intravenously designed to stimulate antigen-presenting cells (APCs) in tumors, enhancing the antitumor immune response. It is being tested alongside chemoradiotherapy in adult patients with LARC at risk for recurrence, as part of the phase 1b FORTRESS trial, which is currently enrolling participants.

Browse the full report description of “Anal and Colorectal Cancer Market Size, Share & Trends Analysis By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), By End-User (Hospitals, Ambulatory Surgery Centers, and Cancer Research Centers), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/anal-and-colorectal-cancer-market

Key Innovators Driving Anal and Colorectal Cancer Transformation

The key players in the Anal and Colorectal Cancer market include Amgen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., Hoffmann-La Roche Ltd., Merck & Co. Inc., among others. These companies are driving innovation in digital health solutions such as telemedicine, electronic health records, remote patient monitoring, and AI-powered clinical tools, shaping the future of healthcare delivery globally.

• FDA has granted fast track designation to NG-350A for treating mismatch repair–proficient locally advanced rectal cancer (LARC). This oncolytic immunotherapy, developed by Akamis Bio, is a T-SIGn therapy delivered intravenously, designed to stimulate antigen-presenting cells (APCs) in tumors, enhancing the antitumor immune response. It is being tested alongside chemoradiotherapy in adult patients with LARC at risk for recurrence, as part of the phase 1b FORTRESS trial, which is currently enrolling participants.
• In May 2025, the FDA approved retifanlimab-dwlr (Zynyz), an immunotherapy for advanced anal cancer, providing new treatment options for patients. This drug targets the PD-1 protein to enhance the immune response against cancer cells. It is approved for two instances: in combination with chemotherapy (carboplatin and paclitaxel) for previously untreated inoperable SCAC, and as a single agent for patients whose cancer has progressed or who cannot tolerate platinum-based chemotherapy. The approval is based on two clinical trials; the Phase 3 POD1UM-303 Trial involved 308 patients, while the Phase 2 POD1UM-202 Trial included 94 patients receiving retifanlimab alone.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Treatment
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Amgen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., Hoffmann-La Roche Ltd., Merck & Co. Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Anal and Colorectal Cancer Market Report Segment

By Treatment

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunothe and ColorectAnarapy

By End-User

• Hospitals
• Ambulatory Surgery Centers
• Cancer Research Centers

Global Anal and Colorectal Cancer Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/anal-and-colorectal-cancer-market